1 Short-Term Relative Effectiveness of Homologous NVX-CoV2373 and BNT162b2 COVID-

- 2 **19 Vaccinations in South Korea**
- 3 Running title: Vaccine Effectiveness of NVX-CoV2373
- 4 Authors: Eunseon Gwak¹*, Seung-Ah Choe^{1,2}*, Erdenetuya Bolormaa¹, Young June Choe¹,
- 5 Chengbin Wang³, Jonathan Fix³, Muruga Vadivale³, and Matthew D. Rousculp³
- 6 Affiliations: ¹Korea University College of Medicine, Seoul, Korea; ²Research and management
- 7 center for health risk of particulate matter, Korea University, Seoul, Korea; ³Novavax, Inc.,
- 8 Gaithersburg, MD, USA.
- 9 *Equally contributed to the manuscript
- 10 Correspondence: Young June Choe, MD, PhD. Department of Pediatrics, Korea University
- 11 College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Korea. Tel: +82-2-920-5090;
- 12 Email: <u>choey@korea.ac.kr</u>; Matthew D. Rousculp, PhD, Real World Evidence, Novavax, Inc., 21
- 13 Firstfield Rd, Gaithersburg, MD 20878. Email: mrousculp@novavax.com
- 14
- 15
- 16
- 17
- 18
- 19

20 Abstract:

21

22 To estimate the relative, short-term effectiveness of NVX-CoV2373 versus BNT162b2 (Pfizer-23 BioNTech) in preventing SARS-CoV-2 infection and severe COVID-19 disease during the 24 Omicron variant dominance in South Korea. Retrospective cohort-study among ≥12-year-olds using the K-COV-N database, which links COVID-19 vaccine registry data with health insurance 25 26 claims data. The Cox proportional-hazards model and inverse probability of treatment weighting 27 were employed to calculate adjusted hazard ratios (aHRs). Among homologous primary-series 28 NVX-CoV2373 versus BNT162b2 recipients, the aHR was 0.86 (95% CI: 0.82–0.91) for all 29 laboratory-confirmed and 0.80 (95% CI: 0.48–1.33) for severe infections. Among homologous 30 1st-booster recipients, it was 0.74 (95% CI: 0.61–0.90) for all laboratory-confirmed and 0.48 (95% 31 CI: 0.12–1.92) for severe infections. At 30-days post-immunization, we observed homologous, 32 NVX-CoV2373 primary-series and 1st-booster offered added protection against SARS-CoV-2 33 infection versus BNT162b2; while there was numerically lower risk of severe disease among 34 NVX-CoV2373-vaccinated, no statistically significant differences were observed.

35

36 Introduction:

37 NVX-CoV2373, a monovalent protein-based SARS-CoV-2 vaccine demonstrated high efficacy against coronavirus disease (COVID-19) in the United States and Mexico (1). As NVX-38 39 CoV2373 is globally integrated into national immunization programs, including South Korea, it 40 is imperative to assess its real-world effectiveness against COVID-19. While evidence indicates 41 NVX-CoV2373 induces similar neutralizing antibody titers as COVID-19 mRNA vaccines, there is limited data on its relative effectiveness in the general population (2). This study aims to 42 43 estimate the relative short-term effectiveness of NVX-CoV2373 compared to BNT162b2 (Pfizer-BioNTech) in preventing SARS-CoV-2 infection and critical COVID-19 during the 44 45 Omicron variant dominance in South Korea, using population-based data.

46

47 **Methods:**

We used the Korea Disease Control and Prevention Agency-COVID-19-National Health 48 49 Insurance Service (K-COV-N) cohort database that links the COVID-19 vaccine registry data 50 with the health insurance claims data (3). Vaccination status includes vaccination date, vaccine 51 type and dose, and place of vaccination. We then constructed a cohort to compare the risk of all 52 laboratory-confirmed and severe SARS-CoV-2 infections (intensive care unit [ICU] admission 53 due to COVID-19 or death within 30-days of SARS-CoV-2 infection) among the NVX-CoV2373 54 vaccine recipients compared with BNT162b2 recipients between February and December 2022. 55 Because the cause of death was unavailable in the data, death after SARS-CoV-2 infection within 56 the risk window was assumed to be related to it. The inclusion criteria capture all persons ≥ 12 57 years with known COVID-19 vaccination status, complete medical outcome data, at least 365-58 days of follow-up before the index date (date of receiving a dose of interest), and residing in 59 South Korea. Our analysis was restricted only to individuals completing homologous primary or 60 booster series immunization.

We estimated propensity scores (PS) for receiving NVX-CoV2373 based on relative income level (medical aid beneficiary and income quartiles), residential region (Seoul capital area or not), disability registration, prior COVID-19 infection history, Charlson comorbidity index assessed in the previous year, and month of the latest immunization. We used PS-based inverse probability of treatment weighting (IPTW) to control for confounding by balancing patient characteristics at baseline. We trimmed the tails of the IPTW distribution observations below a PS of 5% and above a PS of 95% of the vaccinated cohorts, thereby excluding those

68	with extreme values (4). To compare vaccine effectiveness (VE), we estimated the incidence rate
69	(IR per 1000 person-days) and IPTW-adjusted hazard ratios (aHR) of all laboratory-confirmed
70	and severe SARS-CoV-2 infections considering time-varying exposures to vaccination.

The risk window for outcomes was 30-days (NOTE: The risk window started either after 72 7 days (booster) or 14 days (primary series) post-vaccination). For each outcome, individuals 73 were followed for the duration of the risk window until the earliest of one of the following: 74 documentation of the COVID-19 morbidity, death, maximum follow-up duration (30-days), next 75 dose administration, and the end of the study calendar period (December 31, 2022).

The relative VE of NVX-CoV2373 vaccination versus BNT162b2 was assessed regarding overall and severe SARS-CoV-2 infections. The Cox proportional-hazards model was employed to calculate the aHR of SARS-CoV-2 infection, and severe COVID-19 for NVX-CoV2373 compared with BNT162b2. All statistical analyses were performed using SAS[®] 9.4 (SAS Institute, Cary, NC, USA). This study was approved by the Korea University Institutional Review Board (IRB No. 2023AN0124).

82 **Results:**

Among the 137,845 recipients (104,004 for NVX-CoV2373 and 33,841 BNT162b2) of homologous primary series, 17,134 and 4439 received homologous 1st booster doses, and 1,177 and 363 received homologous 2nd booster doses, respectively (Table 1). The NVX-CoV2373 recipients were older, more likely to be male, have a history of prior SARS-CoV-2 infection, have a disability, be employed, and were found to have more comorbidities (CCI \geq 3), and higher income level.

89 Table 2 showed IR and aHR of all laboratory-confirmed and severe SARS-CoV-2 infections following primary series, 1st booster, and 2nd booster of NVX-CoV2373 or BNT162b2 90 91 homologous doses. Among the homologous NVX-CoV2373 primary series recipients, 4884 92 (IR=1.53, 95% CI: 1.48–1.57) experienced an infection, with 58 (IR=0.02; 95% CI: 0.01–0.02) 93 having a severe infection. Among BNT162b2 primary series recipients, 4,249 (IR=4.36; 95% CI: 94 4.23–4.49) had laboratory-confirmed infections, and 34 (IR=0.03; 95% CI: 0.02–0.05) experienced a severe infection. Comparing NVX-CoV2373 to BNT162b2, the aHR was 0.86 (95% 95 96 CI: 0.82–0.91) for all laboratory-confirmed and 0.80 (95% CI: 0.48–1.33) for severe infections. Among homologous 1st booster recipients, the aHR was 0.74 (95% CI: 0.61-0.90) for all 97 98 laboratory-confirmed and 0.48 (95% CI: 0.12–1.92) for severe infections.

99 **Discussion:**

100 In this study, we observed that during the Omicron variant predominance in South Korea, 101 NVX-CoV2373 primary series offered added protection against laboratory-confirmed SARS-102 CoV-2 infection than BNT162b2; while lower risk in NVX-CoV2373 in preventing severe 103 infection, but no statistical significance were observed. Comparable protection was observed after the 1st booster doses of NVX-CoV2373 with BNT162b2, and no comparison was assessed 104 on the 2nd booster dose due to a lack of events after receiving the 2nd booster dose of NVX-105 106 CoV2373 (Table 2). Our finding contrasts with a previous efficacy meta-analysis (5). 107 Nonetheless, our data represent the initial instance demonstrating the variation in effectiveness 108 for homologous doses (2 vs. 2, 3 vs. 3, and 4 vs. 4) of NVX-CoV2373 and BNT162b2 in a vast 109 population-based database.

Several limitations should be considered when interpreting the results. This study relied on health insurance data and may lack information on all confounders, and the variant of previous infections. Furthermore, time since previous infection might have been different across NVX-CoV2373 and BNT162b2, However, the medical guidance in South Korea at the time was to delay receipt of COVID-19 vaccine until 3 months after a confirmed SARS-CoV-2 infection, as such the time since last infection is likely comparable between the two groups.

While we did not measure absolute VE against infection or severe disease compared to unvaccinated, it provides valuable insights on the relative performance of a protein-based vaccine platform compared to the mRNA platform and will help formulate public health strategies. Based on prior immunological studies and our findings, it is advisable to assess the overall benefits and risks of different vaccine platforms in the public's best interest (6).

121 In conclusion, our findings provide needed insight on short-term effectiveness of 122 different COVID-19 vaccine platforms. Furthermore, it underscores the importance for continued 123 vigilance to ensure increased COVID-19 vaccination coverage perhaps through broader vaccine 124 options.

125

126 Funding

127 This work was supported by Novavax, Inc. The sponsor had primary responsibility for study 128 design, protocol development, study monitoring, data management, and statistical analyses. All 129 authors reviewed and approved the manuscript before submission.

130

131 Declaration of Competing Interest

- 132 EG, EB, YJC, and SAC are investigators of the study and do not have any conflicts to report. JF,
- 133 MR, and MV are all employees of Novavax, Inc. and may hold stock in Novavax, Inc. CB used
- to be employed by Novavax, Inc., and holds stock in Novavax, Inc.

135 Acknowledgments

- 136 This study used the Korea Disease Control and Prevention Agency (KDCA) and National Health
- 137 Insurance Service (NHIS) databases for policy and academic research (KDCA-NHIS-2023-1-
- 138 494). The conclusions of this study are not related to this institution.

139 **Contributions:**

- 140 Conceptualization and study design: EG, SC, EB, YJC, CW, and MDR. Data acquisition and
- 141 analysis: EG, SC, EB, and YJC. Data interpretation: EG, SC, EB, YJC, CW, JF, MV, and MDR.
- 142 Drafting of the manuscript and critical review: EG, SC, EB, YJC, CW, JF, MV, and MDR.

143 **References**

- 144 1. Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al.
- 145 Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. The New
- 146 England journal of medicine. 2022 Feb 10;386(6):531-43. PubMed PMID: 34910859. Pubmed

147 Central PMCID: PMC8693692. Epub 2021/12/16. eng.

- 148 2. Mateo-Urdiales A, Sacco C, Petrone D, Bella A, Riccardo F, Del Manso M, et al.
- 149 Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373

150	Against COVID-19	. JAMA network open.	2023 Oct 2;6(10)	:e2336854. PubMed PMID:
-----	------------------	----------------------	------------------	-------------------------

- 151 37792377. Pubmed Central PMCID: PMC10551773. Epub 2023/10/04. eng.
- 152 3. Gwak E, Kim T, Shin JY, Choi NK, Han S, Lee JY, et al. Effectiveness and Safety of
- 153 COVID-19 Vaccination During Preconceptional and Preclinical Pregnancy Period: A National
- 154 Population Study. Journal of Korean medical science. 2023 Oct 23;38(41):e314. PubMed PMID:

155 37873626. Pubmed Central PMCID: PMC10593595. Epub 2023/10/24. eng.

156 4. Stürmer T, Webster-Clark M, Lund JL, Wyss R, Ellis AR, Lunt M, et al. Propensity

157 Score Weighting and Trimming Strategies for Reducing Variance and Bias of Treatment Effect

158 Estimates: A Simulation Study. American journal of epidemiology. 2021 Aug 1;190(8):1659-70.

159 PubMed PMID: 33615349. Pubmed Central PMCID: PMC8327194. Epub 2021/02/23. eng.

160 5. Wu X, Xu K, Zhan P, Liu H, Zhang F, Song Y, et al. Comparative efficacy and safety of

161 COVID-19 vaccines in phase III trials: a network meta-analysis. BMC infectious diseases. 2024

162 Feb 21;24(1):234. PubMed PMID: 38383356. Pubmed Central PMCID: PMC10880292. Epub

163 2024/02/22. eng.

164

1656.Mai F, Kordt M, Bergmann-Ewert W, Reisinger EC, Müller-Hilke B. NVX-CoV2373

166 induces humoral and cellular immune responses that are functionally comparable to vector and

167 mRNA-based vaccines. Frontiers in immunology. 2024;15:1359475. PubMed PMID: 38562927.

168 Pubmed Central PMCID: PMC10982398. Epub 2024/04/02. eng.

169

Table 1. General characteristics of the population who received homologous series of NVX-CoV2373 and BNT162b2 vaccines in South Korea, from February to December 2022

Variables Primary series 1st homologous booster 2nd homologous booster NVX-CoV2373 BNT162b2 Р NVX-CoV2373 BNT162b2 Р NVX-CoV2373 BNT162b2 17,134 4439 Ν 104,004 33,841 1177 363 Age, median 44 (IQR: 26) 36 (IQR: 23) < 0.001 57 (IQR: 29) 57 (IQR: 37) 68 (IQR: 16) 71 (IQR: 16) Sex Male 45,102 (43.4) 7767 (45.3) 1373 (30.9) < 0.001 631 (53.6) 211 (58.1) 0.131 8293 (24.5) < 0.001 Female 58,902 (56.6) 25,548 (75.5) 9367 (54.7) 3066 (69.1) 546 (46.4) 152 (41.9) Non-capital area ^a 52,397 (50.4) 17,163 (50.7) 0.282 8061 (47.1) 506 (43) 0.311 2072 (46.7) 0.66 167 (46) Prior infection 80,559 (77.5) 21,391 (63.2) < 0.001 15,990 (93.3) < 0.001 1175 (99.8) 355 (97.8) 4003 (90.2) < 0.001 Disability 7896 (7.5) 2078 (6.1) < 0.001 2290 (13.4) 604 (13.6) 0.674 213 (18.1) 89 (24.5) 0.007 $CCI \ge 3$ 14,503 (13.9) 3312 (9.8) < 0.001 4000 (23.4) 924 (20.8) < 0.001 461 (39.2) 122 (33.6) 0.056 34,378 (33.1) 7781 (23.0) 683 (15.4) <0.001 25 (6.9) < 0.001 Employed < 0.001 4362 (25.5) 185 (15.7) Income level ^b 1Q (lowest) 1732 (5.4) 1385 (8.3) 537 (12.5) <0.001 138 (11.9) 79 (21.9) 4750 (4.7) < 0.001 < 0.001 2Q 14,456 (14.4) 4107 (12.9) 2450 (14.6) 631 (14.7) 155 (13.4) 59 (16.4) 3Q 6761 (21.2) 834 (19.5) 61 (16.9) 20,019 (19.9) 2988 (17.9) 184 (15.9) 40 25,477 (25.3) 9783 (30.7) 3839 (23.0) 1111 (26.0) 222 (19.1) 73 (20.3) 35,985 (35.7) 1168 (27.3) 5Q (richest) 9455 (29.7) 6069 (36.3) 462 (39.8) 88 (24.4)

^a Non-capital area denotes residence outside of Seoul, Incheon metropolitan city, and Gyeonggi province, included in the Seoul Capital Area of South Korea.

^b Income levels, 1Q, 1st quintile (lowest); 2Q, 2nd quintile, 3Q, 3rd quintile; 4Q, 4th quintile, 5Q, 5th quintile (richest); values missing for 5320 individuals in primary series, 561 in 1st booster, and 19 in 2nd booster vaccination groups.

Abbreviations: CCI, Charlson comorbidity index; IQR, interquartile range

Р

Table 2. Incidence rates (per 1000 person-days) and adjusted hazard ratios, after inverse probability of treatment weighting based on propensity scores, of all laboratory-confirmed and severe SARS-CoV-2 infections among NVX-CoV2373 and BNT162b2 vaccinations in South Korea, from February to December 2022.

Dose	NVX-CoV2373			BNT162b2			aHR (95% CI) ^b
	Event	Person-days	IR (95% CI)	Event	Person-days	IR (95% CI)	
Primary series							
All lab-confirmed infections	4884	3,029053	1.53 (1.48–1.57)	4249	957,188	4.36 (4.23–4.49)	0.86 (0.82–0.91)
Severe infections ^a	50	3,119,176	0.02 (0.01-0.02)	27	1,014,824	0.03 (0.02–0.05)	0.80 (0.48–1.33)
1 st booster							
All lab-confirmed infections	497	506,049	0.94 (0.86–1.03)	98	131,541	0.75 (0.57–0.86)	0.74 (0.61–0.90)
Severe infections	6	513,944	0.01 (0.01-0.03)	3	133,128	0.02 (0.01–0.07)	0.48 (0.12–1.92)
2 nd booster							
All lab-confirmed infections	1	35,230	0.03 (0.00-0.20)	6	10,810	0.56 (0.25–1.24)	0.62 (0.01-59.02)
Severe infections	0	35,310	2.11E-13(0,infty)	1	10,884	0.09 (0.01–0.65)	Unable to assess

^a Severe SARS-CoV-2 infection was defined as intensive care unit (ICU) admission due to COVID-19 and death within 30 days of post-SARS-CoV-2 infection.

^b HR was calculated using inverse probability of treatment weighting (IPTW) based on the propensity score for receiving NVX-CoV2373, with IPTW adjustment for relative level of income, residential region (Seoul capital area or not), disability registration, prior COVID-19 infection history, and the Charlson comorbidity index assessed before the date of latest immunization.

Abbreviation, aHR, IPTW-adjusted hazard ratio; CI, confidence interval; ICU, intensive care unit; IR, incidence rate.